- Corcept Therapeutics (CORT, Financial) to present pivotal Phase 3 ROSELLA trial data at ASCO 2025.
- Study focuses on relacorilant with nab-paclitaxel in platinum-resistant ovarian cancer patients.
- Details set for June 2, 2025, during a late-breaking oral presentation at the ASCO Annual Meeting.
Corcept Therapeutics Incorporated (CORT) is poised to unveil significant findings from its pivotal Phase 3 ROSELLA trial during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial evaluates the efficacy of relacorilant combined with nab-paclitaxel versus nab-paclitaxel alone in patients suffering from platinum-resistant ovarian cancer. The late-breaking oral presentation is scheduled for June 2, 2025, from 8:00 AM to 11:00 AM CDT.
Conducted in collaboration with several esteemed research organizations, including the GOG Foundation, ENGOT, APGOT, LACOG, and ANZGOG, the ROSELLA trial is a critical step in Corcept's engagement with oncologic treatments. Relacorilant, the oral therapy in focus, acts as a selective glucocorticoid receptor antagonist, strategically modulating cortisol activity to potentially enhance chemotherapy efficacy by inhibiting tumor growth and promoting apoptosis.
Platinum-resistant ovarian cancer remains a challenging condition, with limited treatment options available for the approximately 20,000 women affected annually in the United States alone. Relacorilant's potential application in this area highlights Corcept's continued commitment to cortisol modulation as a groundbreaking therapeutic approach in oncology.
Corcept Therapeutics, headquartered in Redwood City, California, continues to explore the vast potential of cortisol modulators. With a robust pipeline that includes more than 1,000 proprietary compounds, Corcept's innovative efforts are not limited to oncology but extend to various severe disorders, including hypercortisolism and ALS. For further details, visit Corcept's official website.
